Literatur
-
1 Martindale. The
Extra Pharmacopoeia, 31th Edition.
-
2
Clark B J, Bucher T, Waite R.
Analysis
of cardiovascular effects of co-dergocrine (Hydergine).
J
Pharmacol.
1985;
16
(suppl
3)
101-111
-
3
Wadworth A N, Chrisp P.
Co-ergocrine mesylate:
a review of its pharmacodynamic and pharmacokinetic properties and
therapeutic use in age-related cognitive decline.
Drugs
Aging.
1992;
2
153-173
-
4
Cayley A CD.
Sinus
bradycardia following treatment with hydergine for cerebrovascular
insufficiency.
Br Med J.
1975;
4
384-385
-
5
Cohen C.
Sinus
bradycardia following treatment with hydergine.
Br Med
J.
1975;
4
581
-
6
Kapoor O P.
Iatrogenic
ergot vasospastic angiitis. A case report.
Vasc Surg.
1976;
10
58-60
-
7
Unseld H.
Vasospasm
following liver rupture, dopamine and hydergine infusion.
Anaesth
Intensivther Notfallmed.
1985;
20
339-341
Autor
Priv.-Doz. Dr. med. Frank Ulrich Müller
Institut für Pharmakologie und Toxikologie, Westfälische
Wilhelms Universität
Domagkstraße 12
48149 Münster
